PrescrYbe Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.3/10
Best for: shoppers who want an oral GLP-1 option or a low-dose microdosing tier
PrescrYbe scores highest on the strength of its clinical program: drug options and dosing support.
Semaglutide
Tirzepatide
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
PrescrYbe is a cash-pay telehealth platform offering compounded semaglutide and tirzepatide as injections or an oral formulation, plus low-dose microdosing tiers from $179. Pricing is billed every 4 weeks rather than monthly and the cadence is stated on the product card. Consultations, medication and shipping are bundled into one price, and you are not charged if a provider finds you ineligible.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Vetted alternatives to PrescrYbe
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Collective
Best for: the lowest flat medication price if you can absorb an annual membership fee
Editorial score · methodology
CoreAge Rx
Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Editorial score · methodology
from $249/4 wks (billed per 4 weeks) · no insurance needed
PrescrYbe at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $249/4 wks (billed per 4 weeks)
- Pricing model
- Flat: dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How we scored PrescrYbe
Each dimension is scored algorithmically from PrescrYbe’s published pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.
Value25%
6.8/10At $249/mo (per 4 weeks), PrescrYbe runs about 39% above the $179 median for GLP-1 providers (each program's lowest listed ongoing monthly price for compounded semaglutide). Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
8.4/10PrescrYbe offers both semaglutide and tirzepatide, the two GLP-1 molecules with the strongest published weight-loss trial outcomes. An oral/needle-free option is offered for patients who avoid injections.
User Experience15%
7.6/10Online intake and platform experience (consult included in the price); 6 platform features disclosed.
Trust & Safety15%
7.5/10Core details confirmed by our editors; no FDA warning letters on file.
Accessibility10%
6.3/10PrescrYbe's exact state footprint isn't published. Confirm coverage in your state before signing up.
Support10%
6.1/10PrescrYbe provides standard clinician follow-up; no extended coaching or community program is disclosed.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this PrescrYbe review
Last checked September 2026- Confirmed current pricing across 5 dose/plan tiers
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the provider's public sign-up flow, stopping before payment
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: medium.
What we checked
- Provider's own pricing page
- $179–$339/mo across 5 dose/plan tiers (checked September 2026)
- FDA warning-letter register
- No letter on file for this provider
What to expect when you sign up with PrescrYbe
We walked PrescrYbe’s public signup flow in September 2026 to document the process (the steps, pricing transparency, and what’s required) before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Pick a treatment on the GLP-1 page. Each card shows the price and the 4-week billing cadence before you click
- 2"Get started" opens PrescrYbe's online intake
- 3First screen is Contact Information: legal first and last name, phone with an international selector, email, a consent checkbox and a reCAPTCHA
- 4Clinical questions sit behind that contact step
- Price and billing cadence are both visible before intake; most sites bury the cadence
- Contact details are collected before any clinical question is asked
- Terms state consultations, medication and shipping are bundled into one price
- No pharmacy partner or prescribing medical group is named anywhere in the terms
PrescrYbe customer support
GLP-1 medications PrescrYbe offers
Tap any medication to read our plain-English guide: how it works, dosing, side effects, and what the trials found.
Pricing
Prices re-verified
Card reads "$249 per 4 week". A 4-week cycle is 13 charges a year, not 12, and the site states the cadence openly.
Card reads "$339 per 4 week".
Card reads "$279 per 4 week" for the oral formulation.
Low-dose tier, "$179 per 4 week".
Low-dose tier, "$179 per 4 week".
Ready to get started?
Plans and promotions change often, so check PrescrYbe's current pricing and active discounts before you decide.
What we like
- Five GLP-1 tiers including an oral semaglutide option and $179 microdosing for both drugs
- Prints the 4-week billing cadence on the product card, which most sites hide
- Price shown before you start intake, not after
- Consultation, medication and shipping bundled into one cash-pay price
- Full refund if a provider finds you ineligible: "If you don't qualify, you don't pay"
Watch-outs
- Charged every 4 weeks, so a year costs 13 payments, not 12 ($3,237/yr on semaglutide, not $2,988)
- Neither the prescribing medical group nor the pharmacy partner is named anywhere in the terms
- No published state list: the terms say only that some services may not be available in all states
- Cancellation is by email to care@prescrybe.health; no self-serve cancel is documented
- No support phone number published
- Compounded only, and the terms confirm compounded drugs are not FDA approved
Is PrescrYbe worth it?
PrescrYbe is built for shoppers who want an oral GLP-1 option or a low-dose microdosing tier. It runs $249/month (per 4 weeks) at every dose; there's no clean category median to weigh that against, but it's a published number rather than one you find out only after signing up. Its standout is a needle-free oral option for people who would rather not inject.
Worth knowing before you sign up: PrescrYbe offers a microdosing option.
How much PrescrYbe costs
Compounded semaglutide runs $249–$279/month depending on plan, the low end listed as “per 4 weeks”, and compounded tirzepatide runs $339/month (per 4 weeks).
Because PrescrYbe's headline figure is listed as “per 4 weeks”, we don't set it against the roughly $179 market median for this category. That median is each program's lowest listed ongoing monthly price for compounded semaglutide, so compare PrescrYbe with the month-to-month prices of the alternatives below instead.
RxSpan MD (about $249/month) is one of the closest alternatives to weigh PrescrYbe against.
Medications: what PrescrYbe prescribes
PrescrYbe prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro), the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products, which is the standard trade-off across the compounded-GLP-1 market.
PrescrYbe's needle-free oral option appeals if you've been avoiding a GLP-1 because of injections. Just set expectations on the science: oral, sublingual and buccal delivery of these peptides is far less studied than the injectable versions the trials used. Treat it as a convenience option, not a proven equal to the shot.
Who PrescrYbe is best for, and who should skip it
A good fit if you…
- are needle-averse and want a non-injectable option, since the oral route skips the weekly injection most GLP-1 programs require.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen instead of a compounded formulation, which this provider doesn't fill.
- need to bill insurance, since like most of this market it's cash-pay with no claims filed on your behalf.
Trust, safety, and medical oversight
We found no FDA warning letter on file for it, though a clean record isn't the same as an endorsement, so read the rest of this review for the full picture. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation, and we explain how in our scoring methodology.
Bottom line
PrescrYbe is a reasonable telehealth GLP-1 option; weigh its pricing and coverage against the alternatives below before deciding.
The Bottom Line
PrescrYbe scores highest on the strength of its clinical program: drug options and dosing support.
Ready to start with PrescrYbe?
From $249/4 wks (billed per 4 weeks). See current pricing and start your free consultation.
PrescrYbe might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Head-to-head
Compare PrescrYbe vs…
PrescrYbe scores7.3/10
Side-by-side pricing, medications and scores. Pick a matchup.
PrescrYbe vs Amazon One Medical
Amazon One Medical scores 8.5/10
PrescrYbe vs Vytora Health
Vytora Health scores 8.4/10
Scores are our independent editorial ratings out of 10.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this PrescrYbe review:
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See PrescrYbe's current pricing
Plans from $249/4 wks (billed per 4 weeks). Start your free consultation to check eligibility and today's price.